Who’s on First? The Expanding Role of Neoadjuvant Therapy in Melanoma
Source: ASCO Daily News, May 2023
- As interest in neoadjuvant treatment in melanoma grows, it’s important to determine the best approaches for investigating new therapeutic agents and post-treatment options for patients.
- An Education Session will explore unanswered questions in understanding clinical outcomes associated with neoadjuvant immunotherapy in melanoma as well as assess several immunotherapy-focused clinical trials.
Recent early-stage clinical trials have provided encouraging data about the potential benefit of neoadjuvant immunotherapy for patients with high-risk, resectable clinical stage III melanoma. As interest in neoadjuvant treatment grows, it is becoming increasingly important to determine the best approaches for investigating new therapeutic agents and managing disease after treatment. These issues will be discussed during the Education Session, “Who’s on First? The Expanding Role of Neoadjuvant Therapy in Melanoma,” which will be held during the 2023 ASCO Annual Meeting on June 6.
“This is an emerging area within melanoma and there has been great success, but there are also a lot of unanswered questions that we hope to highlight,” said Session Chair Rodabe N. Amaria, MD, of The University of Texas MD Anderson Cancer Center.